Hematologic Malignancy
Chronic Leukemia
CI-CAN-00000764Explore in graph →
Hematologic411 active trials10 approved drugs59 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000764Explore in graph →
Clinical trials
1,705 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02015208 | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 13 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT01113632 | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 77 | SCRI Development Innovations, LLCOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01809847 | Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation | completed | Phase 2 | 20 | Technische Universität DresdenOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | completed | Phase 1 | 10 | Fate TherapeuticsINDUSTRY | 1 | Sep 12, 2016 | clinicaltrials |
| NCT02883946 | Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study(RITUX-LEUKEMIA) | completed | — | 41 | CHU de ReimsOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT00771056 | Hydroxychloroquine in Untreated B-CLL Patients | terminated | Phase 2 | 23 | Northwell HealthOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT00046683 | Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | completed | Phase 3 | 284 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jul 28, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 5 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02828774 | Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia | unknown | — | 30 | Assuta Medical CenterOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT01871675 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | completed | Phase 1 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT02110394 | Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia(NORMA) | completed | — | 190 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01649791 | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia | terminated | N/A | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 18 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)(NADIR) | terminated | — | 25 | Astellas Pharma International B.V.INDUSTRY | 7 | Jun 21, 2016 | clinicaltrials |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) | terminated | — | 88 | Stanford UniversityOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)(Rev-CLL) | terminated | Phase 2 | 27 | University Health Network, TorontoOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT01350947 | A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia | completed | Phase 2 | 11 | University of UtahOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00543114 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | terminated | Phase 1 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT01703364 | Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | completed | Phase 1 / Phase 2 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2016 | clinicaltrials |
| NCT01146210 | Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | — | 20 | Children's Oncology GroupNETWORK | 1 | May 17, 2016 | clinicaltrials |
| NCT00330252 | Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL | completed | Phase 1 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT01212380 | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | completed | Phase 1 | 21 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT01056614 | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies | completed | Phase 2 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT02533401 | A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 2 | May 2, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01744626 | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 | 40 | Celgene CorporationINDUSTRY | 2 | Apr 19, 2016 | clinicaltrials |
| NCT00532129 | A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia. | completed | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Apr 6, 2016 | clinicaltrials |
| NCT01398462 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 69 | JW PharmaceuticalINDUSTRY | 2 | Mar 8, 2016 | clinicaltrials |
| NCT02556346 | Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma | withdrawn | Phase 1 | 0 | Molecular Templates, Inc.INDUSTRY | 0 | Mar 2, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide(TAIL) | terminated | Phase 1 | 2 | Baylor College of MedicineOTHER | 1 | Feb 8, 2016 | clinicaltrials |
| NCT00280241 | Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 2 | 65 | University of PittsburghOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19(CART19) | unknown | N/A | 12 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01510756 | Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 4 | Thomas KippsOTHER | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01419691 | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT01892618 | Pneumococcal Vaccine in Untreated CLL Patients | completed | Phase 3 | 134 | Karolinska University HospitalOTHER | 1 | Jan 15, 2016 | clinicaltrials |
| NCT00381004 | FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT01336712 | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases | completed | Phase 2 | 30 | Northside Hospital, Inc.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | terminated | Phase 2 | 6 | Januario Castro, M.D.OTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | terminated | Phase 2 | 5 | Januario Castro, M.D.OTHER | 1 | Dec 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Sep 26, 2016source: clinicaltrials